Brokers Issue Forecasts for Daré Bioscience Q1 Earnings

Daré Bioscience, Inc. (NASDAQ:DARE) – Equities researchers at Brookline Capital Management dropped their Q1 2025 earnings per share (EPS) estimates for Daré Bioscience in a research report issued to clients and investors on Monday, March 31st. Brookline Capital Management analyst K. Dolliver now forecasts that the biotechnology company will post earnings per share of ($0.68) for the quarter, down from their previous forecast of ($0.54). The consensus estimate for Daré Bioscience’s current full-year earnings is ($0.49) per share. Brookline Capital Management also issued estimates for Daré Bioscience’s Q2 2025 earnings at ($0.62) EPS and FY2025 earnings at ($2.48) EPS.

Separately, HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Daré Bioscience in a report on Tuesday.

Daré Bioscience Stock Performance

Shares of DARE opened at $2.89 on Thursday. The company has a market capitalization of $25.14 million, a PE ratio of -4.89 and a beta of 1.38. The company’s 50 day moving average price is $3.03 and its 200 day moving average price is $3.28. Daré Bioscience has a 52 week low of $2.67 and a 52 week high of $7.56.

Daré Bioscience (NASDAQ:DARE) last released its earnings results on Monday, March 31st. The biotechnology company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.66) by $0.02. The business had revenue of ($0.06) million for the quarter, compared to analysts’ expectations of $1.00 million.

Hedge Funds Weigh In On Daré Bioscience

A number of hedge funds have recently added to or reduced their stakes in the company. Jane Street Group LLC bought a new stake in Daré Bioscience in the fourth quarter worth approximately $52,000. Renaissance Technologies LLC lifted its stake in shares of Daré Bioscience by 6.7% in the 4th quarter. Renaissance Technologies LLC now owns 68,695 shares of the biotechnology company’s stock valued at $214,000 after purchasing an additional 4,300 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Daré Bioscience by 4.0% in the fourth quarter. Geode Capital Management LLC now owns 92,653 shares of the biotechnology company’s stock worth $289,000 after purchasing an additional 3,593 shares in the last quarter. Finally, AMH Equity Ltd increased its position in Daré Bioscience by 50.0% during the fourth quarter. AMH Equity Ltd now owns 150,000 shares of the biotechnology company’s stock worth $468,000 after buying an additional 50,000 shares during the last quarter. Institutional investors and hedge funds own 6.70% of the company’s stock.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.